Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;72(8):e31788.
doi: 10.1002/pbc.31788. Epub 2025 May 15.

Medication Utilization Among Children With Sickle Cell Disease in the United States

Abiodun John Ologunowa  1 , Kelly L Matson  1   2 , Jung Eun Lee  3 , Meghan McCormick  1 , Mary L Greaney  4 , Aisling R Caffrey  1
Affiliations

Medication Utilization Among Children With Sickle Cell Disease in the United States

Abiodun John Ologunowa et al. Pediatr Blood Cancer. 2025 Aug.

Abstract

Background and objective: The medication management of children with sickle cell disease (SCD), especially since the release of the 2014 National Heart, Lung, and Blood Institute (NHLBI) SCD treatment guidelines, is not well described in the published literature. This study assessed medication utilization trends overall and by patient demographics.

Methods: This retrospective study examined children aged 1-17 years diagnosed with SCD from January 1, 2010 to December 31, 2018, in Optum's de-identified Clinformatics Data Mart database. Changes in medication utilization over time were assessed using Joinpoint regression. Stratified time trends were evaluated by patient age, sex, race/ethnicity, region, and household income level.

Results: Over the 8-year study period, a total of 1868 children with SCD were identified. Hydroxyurea prescriptions increased 8.8%, on average, each year of the study period (p < 0.001), indicating rising adherence to recommended disease-modifying strategies. Shifts in opioid prescribing showed increased oxycodone use (6.3% average annual increase, p < 0.001) and decreased acetaminophen-codeine use (24.3% average annual decrease, p < 0.001). Notably, non-steroidal anti-inflammatory drug (NSAID) use increased by 4.0% annually (p = 0.010), reflecting shifts toward alternative pain management strategies. Significant shifts in medication utilization, overall and by patient demographics, were observed since the 2014 NHLBI SCD treatment guidelines were released.

Conclusions: Our study findings underscore the dynamic nature of SCD management in children, and highlight the need for continuous evaluation of treatment guideline adherence, as well as treatment effectiveness and safety with the newer SCD medications and treatment guidelines, to optimize clinical outcomes among this vulnerable patient population.

Keywords: hydroxyurea; opioids; pediatrics; sickle cell disease.

PubMed Disclaimer

References

    1. A. M. Thomson, T. A. McHugh, A. P. Oron, et al., “Global, Regional, and National Prevalence and Mortality Burden of Sickle Cell Disease, 2000–2021: A Systematic Analysis From the Global Burden of Disease Study 2021,” Lancet Haematology 10, no. 8 (2023): e585–e599, https://doi.org/10.1016/S2352‐3026(23)00118‐7.
    1. M. Stokoe, H. M. Zwicker, C. Forbes, et al., “Health Related Quality of Life in Children With Sickle Cell Disease: A Systematic Review and Meta‐analysis,” Blood Reviews 56 (2022): 100982, https://doi.org/10.1016/j.blre.2022.100982.
    1. C. E. Beck, E. D. Trottier, M. Kirby‐Allen, and Y. Pastore, “Acute Complications in Children With Sickle Cell Disease: Prevention and Management,” Paediatrics & Child Health 27, no. 1 (2022): 50–62, https://doi.org/10.1093/pch/pxab096.
    1. “FDA Approves Hydroxyurea For Treatment Of Pediatric Patients With Sickle Cell Anemia,” FDA, February 9, 2019, https://www.fda.gov/drugs/resources‐information‐approved‐drugs/fda‐appro....
    1. Emmaus Medical, Inc, “A Phase III, Prospective, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group, Multicenter Study Of L Glutamine Therapy For Sickle Cell Anemia And Sickle SS0‐Thalassemia,” clinicaltrials.gov, 2020, https://clinicaltrials.gov/study/NCT01179217.

LinkOut - more resources